|Mr. Bruno Grange||International Controller and Director||131.38k||N/A||64|
|Ms. Valérie Poinsot||Director of Devel., Deputy Gen. Mang. and Exec. Director||1.02M||N/A||48|
|Mr. Jean-Christophe Bayssat||Chief Pharmacist, Director of Pharmaceutical Devel. and Deputy Gen. Mang.||981.46k||N/A||54|
|Mr. Christian Boiron||Gen. Mang. and Exec. Director||865.52k||N/A||69|
|Fabrice Rey||Group Treasurer||N/A||N/A||N/A|
Boiron SA, through its subsidiaries, engages in the manufacture and sale of homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded homeopathic medicines. Its branded homeopathic medicines are used for the treatment of influenza symptoms; coughs; benign trauma in the absence of open wounds; hematomas, bruising, contusions, and muscle fatigue; teething problems for nursing babies; anxiety and emotional disorders, and minor sleep disorders; cold symptoms and rhinitis; ocular discomfort and irritation due to various causes for adults and children; and vocal disorders. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Boiron SA’s ISS governance QualityScore as of 2 June 2017 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder rights: 7; Compensation: 9.